VectivBio AG clinical trials
Acquired by Ironwood Pharmaceuticals, Inc., Jun 29, 2023 · source ↗
The registry lists 9 studies whose lead sponsor is VectivBio AG. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 4, 2026.
Before and after it joined Ironwood Pharmaceuticals, Inc.
- First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- 7
- First submitted after VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- VectivBio AG9 studies
Something wrong with this grouping? Tell us on the Ironwood Pharmaceuticals, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Ironwood Pharmaceuticals, Inc. studies →
- A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)RecruitingNCT07742735Phase 3
Sponsor listed in the registry: VectivBio AG · First submitted after VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)TerminatedNCT05415410Phase 2
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT05706623Phase 1
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.Active, not recruitingNCT05018286Phase 3
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)CompletedNCT04964986Phase 2
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFCompletedNCT04627025Phase 3
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference FormulationCompletedNCT06002555Phase 1
Sponsor listed in the registry: VectivBio AG · First submitted after VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.CompletedNCT04699032Phase 1
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.
- Evaluation of Apraglutide on Gastric EmptyingCompletedNCT05995704Phase 1
Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.